P190A RhoGAP is involved in EGFR pathways and promotes proliferation, invasion and migration in lung adenocarcinoma cells

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1569-1577

  Notsuda, Hirotsugu ^a   Sakurada, Akira ^a   Endo, Chiaki ^a   Okada, Yoshinori ^a   Horii, Akira ^b   Shima, Hiroshi ^c   Kondo, Takashi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MIYAGI CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

EGFR; Lung cancer; P190 A RhoGAP; Phosphorylation; Therapeutic target

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MESSENGER RNA; PROTEIN P190; SMALL INTERFERING RNA;

AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA CELL; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR INVASION;

ADENOCARCINOMA; AGED; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84885037305     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2096     Document Type: Article

References (25)

1. Baselga J and Averbuch SD: ZD1839 ('Iressa') as an anticancer agent. Drugs 60: 33-40, 2000.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2: 123-132, 2005.
3. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 16: 2149-2158, 2003.
4. Inoue A, Suzuki T, Fukuhara T, et al: Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 21: 3340-3346, 2006.
5. Yun CH, Mengwasser KE, Toms AV, et al: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 6: 2070-2075, 2008.
6. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 5827: 1039-1043, 2007.
7. Guha U, Chaerkady R, Marimuthu A, et al: Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci USA 37: 14112-14117, 2008.
8. Arthur WT and Burridge K: RhoA inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity. Mol Biol Cell 9: 2711-2720, 2001.
9. Tikoo A, Czekay S, Viars C, et al: p190-A, a human tumor suppressor gene, maps to the chromosomal region 19q13.3 that is reportedly deleted in some gliomas. Gene 1: 23-31, 2000.
10. Roof RW, Haskell MD, Dukes BD, Sherman N, Kinter M and Parsons SJ: Phosphotyrosine (p-Tyr)-dependent and -independent mechanisms of p190 RhoGAP-p120 RasGAP interaction: Tyr 1105 of p190, a substrate for c-Src, is the sole p-Tyr mediator of complex formation. Mol Cell Biol 12: 7052-7063, 1998.
11. Moran MF, Polakis P, McCormick F, Pawson T and Ellis C: Protein-tyrosine kinases regulate the phosphorylation, protein interactions, subcellular distribution and activity of p21ras GTPase-activating protein. Mol Cell Biol 4: 1804-1812, 1991.
12. Kusama T, Mukai M, Endo H, et al: Inactivation of Rho GTPases by p190 RhoGAP reduces human pancreatic cancer cell invasion and metastasis. Cancer Sci 9: 848-853, 2006.
13. Shen CH, Chen HY, Lin MS, et al: Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration and invasion. Cancer Res 19: 7779-7787, 2008.
14. Moon SY and Zheng Y: Rho GTPase-activating proteins in cell regulation. Trends Cell Biol 1: 13-22, 2003.
15. Costa DB, Halmos B, Kumar A, et al: BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 10: 1669-1679, 2007.
16. Mitchell CE, Belinsky SA and Lechner JF: Detection and quantitation of mutant K-ras codon 12 restriction fragments by capillary electrophoresis. Anal Biochem 1: 148-153, 1995.
17. Forbes S, Clements J, Dawson E, et al: Cosmic 2005. Br J Cancer 2: 318-322, 2006.
18. Massarelli E, Varella-Garcia M, Tang X, et al: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 10: 2890-2896, 2007.
19. Detterbeck FC, Boffa DJ and Tanoue LT: The new lung cancer staging system. Chest 1: 260-271, 2009.
20. Ma L, Liu YP, Geng CZ, Wang XL, Wang YJ and Zhang XH: Over expression of RhoA is associated with progression in invasive breast duct carcinoma. Breast J 1: 105-107, 2010.
21. Xiaorong L, Wei W, Liyuan Q and Kaiyan Y: Underexpression of deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma. BMC Cancer 8: 205, 2008.
22. Dittert DD, Kielisch C, Alldinger I, et al: Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis. Hum Pathol 7: 1002-1010, 2008.
23. Takenawa T and Miki H: WASP and WAVE family proteins: key molecules for rapid rearrangement of cortical actin filaments and cell movement. J Cell Sci 10: 1801-1809, 2001.
24. Tsubakimoto K, Matsumoto K, Abe H, et al: Small GTPase RhoD suppresses cell migration and cytokinesis. Oncogene 15: 2431-2440, 1999.
25. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 1: 11-22, 2003.